What powers Omada? ➡️ Clinical evidence shapes commercial strategy ➡️ Technology scales our services and lowers costs ➡️ Human coaching fuels engagement and quality ➡️ Outcomes guide innovation Together, these create a cycle of innovation, with our members always at the center. $OMDA

Omada’s Clinical Research Scientist Lisa Stanton, PhD, takes the stage at @world_obesity for an oral presentation on a question coming up more often in GLP-1 care: how to improve the quality of weight loss, along with the amount. She'll walk through Omada's 12-week comparative study, recently published in the Journal of Diabetes, Obesity and Metabolism. On average, people in Omada's GLP-1 Care Track reduced body fat percentage about twice as much as those receiving standard care. Learn more: ow.ly/BZ6A50ZZaQt

Today at our Investor Day, we are introducing updated long-term financial targets: 80% non-GAAP gross margin, 30% adjusted EBITDA margin, and continued annual revenue growth of at least 20%. The webcast begins at 1pm ET. Learn more here: ow.ly/wKVY50ZM3jX $OMDA

A new independent model from @globaldataplc estimates up to $11,142 in cumulative per-member savings for Omada's GLP-1 program at five years, driven by medication persistence, engagement, and disease-risk reduction. Read more: ow.ly/yvPO50ZLzsT

🚨New peer-reviewed study alert! Omada’s latest publication examined the impact of our diabetes program combined with wearable continuous glucose monitoring (CGM) technology. Spoiler: Omada + CGM tech = a potent product. Read the full study here: omadahealth.com/resource-cen…

$OMDA Q2 2026 highlights: 📈 $88M revenue (+43% YoY) 📊 73% gross margin 💫 $11M adjusted EBITDA 👥 Total Members +45% YoY Our most profitable quarter to date. investors.omadahealth.com/ne…

Health plans are closer to a dynamic that isn’t always visible elsewhere: as GLP‑1 demand grows, so do point solutions. The result is fragmented care—and diminishing returns for plans and members alike.

What would it look like to recommend a single partner that can flex across the variability you’re seeing with clients?

The moment calls for a partner built for change; one that allows you to make a recommendation that holds up as conditions shift, without asking clients to choose between cost control and employee support.

These pressures go beyond a simple cover vs. don’t cover decision. They can cause clients to weigh runaway pharmacy costs against facing employee backlash when coverage isn’t offered, along with the reality that weight health needs may go unmet.

We recently hosted the webinar “The Story Between Visits: A New Lens on Cardiometabolic Care.” Here’s how MercerWell’s Tylane Garrett framed the stakes: "Employers should be wary of fragmented solutions that leave members to piece together their own care." benefitnews.com/web-seminars…

For employers saying yes to coverage, saying no for now, or somewhere in between, there’s a flexible, budget-conscious path forward—one that doesn’t force a tradeoff between cost and care. That’s the kind of GLP‑1 strategy we help build.

Because the landscape is shifting fast, our GLP‑1 strategies are built to flex with employers’ changing cost realities. We adapt as scenarios shift, while maintaining continuous employee support around weight health that has been proven to drive sustainable outcomes.

As GLP-1 adoption drives the next era of cardiometabolic care for Americans, Omada incorporates prescribing and guided care to help support members. ow.ly/ez8Y50Zq7p9

The relationship between muscle loss & GLP-1s is… complicated. New data from Omada shows that with the right support, people on GLP‑1s aren't just losing weight—they’re changing how they move, function, & feel in ways traditional metrics often miss. omadahealth.com/resource-cen…

A happy, healthy 4th of July from Omada! Today and everyday we're committed to making happy, healthy lives more accessible, more equitable, and more sustainable for the members we serve. #4thofJuly #IndependenceDay